TQB2450
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQB2450 is one of 386 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
14
Indications
34
Total Trials
6
Active Trials
385
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1TQB2450
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Trodelvy
GileadPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer6 trials
Small Cell Lung Cancer3 trials
Anlotinib2 trials
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Unknown status·—·Phase 3·NCT04665609·80 enrolled
Patients With Advanced Solid Tumors2 trials
16 more indications
Endometrial Cancer2 trials
Lung Cancer2 trials
Lymphoma2 trials
Cervical Cancer1 trial
Adenocarcinoma1 trial
Nasopharyngeal Carcinoma1 trial
Advanced Renal Cancer1 trial
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolledCholangiocarcinoma1 trial
Melanoma1 trial
Esophageal Squamous Cell Carcinoma1 trial
Paclitaxel1 trial
Adjuvant Therapy1 trial
Second-line Treatment1 trial
Hepatocellular Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQB2450. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details